Regenerate with Regeneron

Regeneron Pharmaceuticals, Inc. (REGN - Analyst Report) is a biopharmaceutical company engaged in the development and marketing of therapeutic medicines for the treatment of serious medical conditions. Its lead candidates are VEGF-Trap for the treatment of cancers, eye diseases, and IL-1 Trap for CAPS and gout.

The company recently received the FDA approval of Arcalyst for CAPS [CIAS1-Associated Periodic Syndrome, a rare genetic disorder]. It also has a number of pre-clinical drug candidates for other disorders.

The company made impressive progress in recent months in terms of clinical advances and business developments. We maintain our Buy rating on its shares with a price target of $28.

Read the full analyst report on REGN